 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of acute liver [0m
[34minjury?[0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"TIGECYCLINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: TIGECYCLINE: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: All-Cause Mortality [0m[31m Mortality Imbalance and Lower Cure [0m
[31mRates in Hospital-Acquired Pneumonia [0m[31m Anaphylaxis [0m[1;31m[[0m[31mWarning and Precautions [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Hepatic Adverse Effects [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Pancreatitis [0m[1;31m[[0m[31mWarnings and Precautions [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[1;31m][0m[31m The most [0m
[31mcommon adverse reactions [0m[1;31m([0m[31mincidence >[0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. [0m[1;31m([0m[31m [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Apotex at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m706[0m[31m-[0m[1;31m5575[0m[31m [0m
[31mor FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www. TIGECYCLINE: adverse_reactions: da.gov/medwatch [0m[1;31m6.1[0m[31m Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction [0m
[31mrates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, [0m[1;31m2514[0m
[31mpatients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in [0m[1;31m7[0m[31m% of patients compared to [0m[1;31m6[0m[31m% for all comparators. Table [0m[1;31m1[0m[31m shows the [0m
[31mincidence of adverse reactions through test of cure reported in â‰¥[0m[1;31m2[0m[31m% of patients in these trials. Table [0m[1;31m1[0m[31m. TIGECYCLINE: adverse_reactions: Incidence [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Adverse Reactions Through Test of Cure [0m
[31mReported in â‰¥ [0m[1;31m2[0m[31m% of Patients Treated in Clinical Studies Body System Tigecycline for injection Comparators a Adverse Reactions [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2514[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m2307[0m[1;31m)[0m[31m a Vancomycin/Aztreonam, Imipenem/Cilastatin, [0m
[31mLevofloxacin, Linezolid. b LFT abnormalities in tigecycline for injection-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which [0m
[31moccurred more often on therapy. TIGECYCLINE: adverse_reactions: Body as a Whole Abdominal pain [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Abscess [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Asthenia [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Headache [0m[1;31m6[0m[31m [0m[1;31m7[0m[31m Infection [0m[1;31m7[0m[31m [0m[1;31m5[0m[31m Cardiovascular System Phlebitis [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m Digestive [0m
[31mSystem Diarrhea [0m[1;31m12[0m[31m [0m[1;31m11[0m[31m Dyspepsia [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Vomiting [0m[1;31m18[0m[31m [0m[1;31m9[0m[31m Hemic and Lymphatic System Anemia [0m[1;31m5[0m[31m [0m[1;31m6[0m[31m Metabolic and Nutritional Alkaline Phosphatase Increased [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Amylase Increased [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Bilirubinemia [0m[1;31m2[0m[31m [0m
[1;31m1[0m[31m BUN Increased [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m Healing Abnormal [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Hyponatremia [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m Hypoproteinemia [0m[1;31m5[0m[31m [0m[1;31m3[0m[31m SGOT Increased b [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m SGPT Increased b [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m Respiratory System Pneumonia [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Nervous System Dizziness [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Skin and [0m
[31mAppendages Rash TIGECYCLINE: adverse_reactions: [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m In all [0m[1;31m13[0m[31m Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m trials that included a comparator, death occurred in [0m[1;31m4.0[0m[31m% [0m[1;31m([0m[1;31m150[0m[31m/[0m[1;31m3788[0m[1;31m)[0m[31m of patients receiving tigecycline and [0m[1;31m3.0[0m[31m% [0m[1;31m([0m[1;31m110[0m[31m/[0m[1;31m3646[0m[1;31m)[0m[31m [0m
[31mof patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, an adjusted risk difference of all-cause mortality was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m
[1;31m1.2[0m[1;31m)[0m[31m between tigecycline for injection and comparator-treated patients [0m[1;31m([0m[31msee Table [0m[1;31m2[0m[1;31m)[0m[31m. The cause of the imbalance has not been established. Generally, deaths were the result of worsening infection, [0m
[31mcomplications of infection or underlying co-morbidities. Table [0m[1;31m2[0m[31m. TIGECYCLINE: adverse_reactions: Patients with Outcome of Death by Infection Type Tigecycline for Injection Comparator Risk Difference*[0m
[31mInfection Type n/N % n/N % % [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m CAP = Community-acquired pneumonia; cIAI = Complicated intra-abdominal infections; cSSSI = Complicated skin and skin structure infections; HAP = Hospital-acquired[0m
[31mpneumonia; VAP = Ventilator-associated pneumonia; RP = Resistant pathogens; DFI = Diabetic foot infections. * The difference between the percentage of patients who died in tigecycline for injection [0m
[31mand comparator treatment groups. The [0m[1;31m95[0m[31m% CI for each infection type was calculated using the normal approximation method without continuity correction. ** Overall adjusted [0m[1;31m([0m[31mrandom effects model by [0m
[31mtrial weight[0m[1;31m)[0m[31m risk difference estimate and [0m[1;31m95[0m[31m% CI. a These are subgroups of the HAP population.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: adverse_reactions: In patients treated for community-acquired bacterial pneumonia [0m[1;31m([0m[31mCABP[0m[1;31m)[0m[31m, nausea incidence was [0m[1;31m24[0m[31m% for tigecycline for injection and [0m[1;31m8[0m[31m% for levofloxacin; vomiting[0m
[31mincidence was [0m[1;31m16[0m[31m% for tigecycline for injection and [0m[1;31m6[0m[31m% for levofloxacin. Discontinuation from tigecycline for injection was most frequently associated with nausea [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m and vomiting [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m. For [0m
[31mcomparators, discontinuation was most frequently associated with nausea [0m[1;31m([0m[31m<[0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m. TIGECYCLINE: adverse_reactions: The following adverse reactions were reported [0m[1;31m([0m[31m<[0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m in patients receiving tigecycline for[0m
[31minjection in clinical studies: Body as a Whole : injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection [0m
[31msite phlebitis Cardiovascular System: thrombophlebitis Digestive System: anorexia, jaundice, abnormal stools Metabolic/Nutritional System: increased creatinine, hypocalcemia, hypoglycemia Special [0m
[31mSenses: taste perversion Hemic and Lymphatic System : prolonged activated partial thromboplastin time [0m[1;31m([0m[31maPTT[0m[1;31m)[0m[31m, prolonged prothrombin time [0m[1;31m([0m[31mPT[0m[1;31m)[0m[31m, eosinophilia, increased international normalized ratio [0m
[1;31m([0m[31mINR[0m[1;31m)[0m[31m, thrombocytopenia Skin and Appendages: pruritus Urogenital System: vaginal moniliasis, vaginitis, leukorrhea [0m[1;31m6[0m[31m. TIGECYCLINE: adverse_reactions: [0m[1;31m2[0m[31m Post-Marketing Experience The following adverse [0m
[31mreactions have been identified during post-approval use of tigecycline for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to[0m
[31mreliably estimate their frequency or establish causal relationship to drug exposure. anaphylactic reactions acute pancreatitis hepatic cholestasis, and jaundice severe skin reactions, including [0m
[31mStevens-Johnson Syndrome symptomatic hypoglycemia in patients with and without diabetes mellitus hypofibrinogenemia [0m[1;31m[[0m[31msee Warnings and Precautions [0m[1;31m([0m[1;31m5[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and [0m
[31melectrolyte management, protein supplementation, antibacterial drug treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. [0m[1;31m5.10[0m[31m Sepsis/Septic Shock in [0m
[31mPatients With Intestinal Perforation Monotherapy with tigecycline should be avoided in patients with complicated intra-abdominal infections [0m[1;31m([0m[31mcIAI[0m[1;31m)[0m[31m secondary to clinically apparent intestinal [0m
[31mperforation. In cIAI studies [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m1642[0m[1;31m)[0m[31m, [0m[1;31m6[0m[31m patients treated with tigecycline for injection and [0m[1;31m2[0m[31m patients treated with imipenem/cilastatin presented with intestinal perforations and developed [0m
[31msepsis/septic shock. TIGECYCLINE: warnings_and_cautions: The [0m[1;31m6[0m[31m patients treated with tigecycline for injection had higher APACHE II scores [0m[1;31m([0m[31mmedian = [0m[1;31m13[0m[1;31m)[0m[31m versus the [0m[1;31m2[0m[31m patients treated with [0m
[31mimipenem/cilastatin [0m[1;31m([0m[31mAPACHE II scores = [0m[1;31m4[0m[31m and [0m[1;31m6[0m[1;31m)[0m[31m. Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment [0m
[31mcannot be established. [0m[1;31m5.11[0m[31m Tetracycline-Class Adverse Effects Tigecycline for injection is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects. Such [0m
[31meffects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action [0m[1;31m([0m[31mwhich has led to increased BUN, azotemia, acidosis, and hyperphosphatemia[0m[1;31m)[0m[31m. [0m[1;31m5[0m[31m. TIGECYCLINE: warnings_and_cautions:[0m
[1;31m12[0m[31m Development of Drug-Resistant Bacteria Prescribing tigecycline for injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and [0m
[31mincreases the risk of the development of drug-resistant bacteria.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: package_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: generic_name         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: overdosage: [0m[1;31m10[0m[31m OVERDOSAGE No specific information is available on the treatment of overdosage with tigecycline. Intravenous administration of tigecycline for injection at a [0m
[31msingle dose of [0m[1;31m300[0m[31m mg over [0m[1;31m60[0m[31m minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting. Tigecycline is not removed in significant quantities by hemodialysis.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials demonstrated an increase in all-cause mortality in [0m
[31mtigecycline for injection-treated patients compared to controls with a risk difference of [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this increase has not been established. An increase was also seen in a [0m
[31mmeta-analysis limited to the approved indications [0m[1;31m[[0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[1;31m][0m[31m. The greatest difference in mortality was seen in tigecycline for injection-treated patients with ventilator-associated [0m
[31mpneumonia. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Anaphylactic Reactions: have been reported with tigecycline for injection and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m.[0m
[31mTIGECYCLINE: warnings_and_cautions: [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m Hepatic Adverse Effects: have been reported with tigecycline for injection. Patients who develop abnormal liver function tests during tigecycline for injection [0m
[31mtherapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Pancreatitis: including fatalities, has been reported [0m
[31mwith tigecycline for injection. If pancreatitis is suspected, then consider stopping tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Monitoring Blood Coagulation Parameters: Hypofibrinogenemia has been reported [0m
[31mwith tigecycline for injection. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mwarnings_and_cautions: [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m Tooth Discoloration and Enamel Hypoplasia: The use of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m [0m
[31myears[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m and enamel hypoplasia. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Inhibition of Bone Growth: The use of tigecycline for injection during the second and third [0m
[31mtrimester of pregnancy, infancy, and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. [0m[1;31m([0m[31m [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Clostridium difficile associated Diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m: evaluate if diarrhea [0m
[31moccurs. [0m[1;31m([0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for injection-treated patients versus [0m
[31mcomparator-treated patients. TIGECYCLINE: warnings_and_cautions: In all [0m[1;31m13[0m[31m Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m trials that included a comparator, death occurred in [0m[1;31m4.0[0m[31m% [0m[1;31m([0m[1;31m150[0m[31m/[0m[1;31m3788[0m[1;31m)[0m[31m of patients receiving tigecycline for [0m
[31minjection and [0m[1;31m3.0[0m[31m% [0m[1;31m([0m[1;31m110[0m[31m/[0m[1;31m3646[0m[1;31m)[0m[31m of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, the adjusted risk difference of all-cause [0m
[31mmortality was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m between tigecycline for injection and comparator-treated patients. An analysis of mortality in all trials conducted for approved indications [0m[1;31m([0m[31mcSSSI, cIAI, and [0m
[31mCABP[0m[1;31m)[0m[31m, including post-market trials showed an adjusted mortality rate of [0m[1;31m2.5[0m[31m% [0m[1;31m([0m[1;31m66[0m[31m/[0m[1;31m2640[0m[1;31m)[0m[31m for tigecycline and [0m[1;31m1.8[0m[31m% [0m[1;31m([0m[1;31m48[0m[31m/[0m[1;31m2628[0m[1;31m)[0m[31m for comparator, respectively.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: The adjusted risk difference for mortality stratified by trial weight was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this mortality difference has not been [0m
[31mestablished. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. Tigecycline for injection should be reserved for use in situations when [0m
[31malternative treatments are not suitable [0m[31m . [0m[1;31m5.2[0m[31m Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia A trial of patients with hospital acquired, including ventilator-associated, [0m
[31mpneumonia failed to demonstrate the efficacy of tigecycline for injection. TIGECYCLINE: warnings_and_cautions: In this trial, patients were randomized to receive tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg [0m
[31minitially, then [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who [0m
[31mreceived tigecycline for injection had lower cure rates [0m[1;31m([0m[1;31m47.9[0m[31m% versus [0m[1;31m70.1[0m[31m% for the clinically evaluable population[0m[1;31m)[0m[31m. In this trial, greater mortality was seen in patients with ventilator-associated [0m
[31mpneumonia who received tigecycline for injection [0m[1;31m([0m[1;31m25[0m[31m/[0m[1;31m131[0m[31m [0m[1;31m[[0m[1;31m19.1[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m15[0m[31m/[0m[1;31m122[0m[31m [0m[1;31m[[0m[1;31m12.3[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m [0m[31m . Particularly high mortality was seen among tigecycline for injection-treated [0m
[31mpatients with ventilator-associated pneumonia and bacteremia at baseline [0m[1;31m([0m[1;31m9[0m[31m/[0m[1;31m18[0m[31m [0m[1;31m[[0m[1;31m50.0[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m1[0m[31m/[0m[1;31m13[0m[31m [0m[1;31m[[0m[1;31m7[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m7[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m. [0m[1;31m5.3[0m[31m Anaphylactic [0m
[31mReactions Anaphylactic reactions have been reported with nearly all antibacterial agents, including tigecycline for injection, and may be life-threatening. Tigecycline for injection is structurally [0m
[31msimilar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs. [0m[1;31m5.4[0m[31m Hepatic Adverse Effects Increases in [0m
[31mtotal bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been [0m
[31mreported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. TIGECYCLINE: warnings_and_cautions: Patients who develop abnormal liver [0m
[31mfunction tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur[0m
[31mafter the drug has been discontinued. [0m[1;31m5.5[0m[31m Pancreatitis Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be [0m
[31mconsidered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk [0m
[31mfactors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having [0m
[31mdeveloped pancreatitis [0m[31m . [0m[1;31m5[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m6[0m[31m Monitoring of Blood Coagulation Parameters Hypofibrinogenemia has been reported in patients treated with tigecycline for injection [0m[31m .[0m
[31mObtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecycline for injection. [0m[1;31m5.7[0m[31m Tooth Discoloration and Enamel Hypoplasia The[0m
[31muse of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m years[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m. [0m
[31mThis adverse reaction is more common during long-term use of tetracyclines, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TIGECYCLINE: [0m
[31mwarnings_and_cautions: Advise the patient of the potential risk to the fetus if tigecycline for injection is used during the second or third trimester of pregnancy [0m[31m. [0m[1;31m5.8[0m[31m Inhibition of Bone Growth The [0m
[31muse of tigecycline for injection during the second and third trimester of pregnancy, infancy and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. All tetracyclines [0m
[31mform a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of [0m[1;31m25[0m[31m mg/kg every [0m[1;31m6[0m[31m hours. This [0m
[31mreaction was shown to be reversible when the tetracycline was discontinued. Advise the patient of the potential risk to the fetus if tigecycline for injection is used during the second or third [0m
[31mtrimester of pregnancy [0m[1;31m[[0m[31msee Use in Specific Populations [0m[1;31m([0m[1;31m8[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Tigecycline has been reported to have hepatic adverse effects. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening [0m
[32mhepatic function and evaluated for the risk/benefit of continuing tigecycline therapy. Increases in total bilirubin concentration, prothrombin time, and transaminases have been seen in patients [0m
[32mtreated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline, although some of these patients were [0m
[32mreceiving multiple concomitant medications. Hepatic dysfunction may occur after the drug has been discontinued.[0m

[32mSOURCE: TIGECYCLINE label[0m
[32mEXTRACT_START_END: Hepatic Adverse Effects: have been reported[0m[32m...[0m[32m continuing tigecycline therapy.[0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Tigecycline has been reported to have hepatic adverse [0m
[34meffects. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for the risk/benefit of continuing [0m
[34mtigecycline therapy. Increases in total bilirubin concentration, prothrombin time, and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic [0m
[34mdysfunction and hepatic failure have been reported in patients being treated with tigecycline, although some of these patients were receiving multiple concomitant medications. Hepatic dysfunction may [0m
[34moccur after the drug has been discontinued.[0m

[34mSOURCE: TIGECYCLINE label[0m
[34mEXTRACT_START_END: Hepatic Adverse Effects: have been reported[0m[34m...[0m[34m continuing tigecycline therapy.[0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if TIGECYCLINE increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that TIGECYCLINE has been reported to have hepatic adverse effects, including increases in total bilirubin concentration, prothrombin time, and transaminases. Isolated [0m
[32mcases of significant hepatic dysfunction and hepatic failure have been reported, although some of these patients were receiving multiple concomitant medications. Patients with abnormal liver function [0m
[32mtests during tigecycline therapy should be monitored for worsening hepatic function."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"TIGECYCLINE can increase the risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if TIGECYCLINE increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that TIGECYCLINE has been reported to have hepatic adverse effects, including increases in total bilirubin concentration, prothrombin time, and transaminases. Isolated [0m
[34mcases of significant hepatic dysfunction and hepatic failure have been reported, although some of these patients were receiving multiple concomitant medications. Patients with abnormal liver function [0m
[34mtests during tigecycline therapy should be monitored for worsening hepatic function."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"TIGECYCLINE can increase the risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if TIGECYCLINE increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that TIGECYCLINE has been reported to have hepatic adverse effects, including increases in total bilirubin concentration, prothrombin time, and transaminases. Isolated cases of[0m
[31msignificant hepatic dysfunction and hepatic failure have been reported, although some of these patients were receiving multiple concomitant medications. Patients with abnormal liver function tests [0m
[31mduring tigecycline therapy should be monitored for worsening hepatic function.[0m
[31m        -----[0m
[31m        Final answer: TIGECYCLINE can increase the risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is correct and consistent with medical knowledge. Tigecycline has been reported to have hepatic adverse effects, which can include acute liver injury. The [0m
[32mresponse from FDAHandler is trusted and aligns with the known side effects of the medication. Therefore, there are no flaws in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is correct and consistent with medical knowledge. Tigecycline has been reported to have hepatic adverse effects, which can include acute liver injury. The [0m
[34mresponse from FDAHandler is trusted and aligns with the known side effects of the medication. Therefore, there are no flaws in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is correct and consistent with medical knowledge. Tigecycline has been reported to have hepatic adverse effects, which can include acute liver injury. The [0m
[31mresponse from FDAHandler is trusted and aligns with the known side effects of the medication. Therefore, there are no flaws in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mTIGECYCLINE can increase the risk of acute liver injury. This is supported by the response from FDAHandler, which indicates that hepatic adverse effects, including increases in total bilirubin [0m
[32mconcentration, prothrombin time, and transaminases, have been reported in patients treated with tigecycline. Additionally, isolated cases of significant hepatic dysfunction and hepatic failure have [0m
[32mbeen reported, although it is noted that some of these patients were receiving multiple concomitant medications. Monitoring for worsening hepatic function is recommended for patients who develop [0m
[32mabnormal liver function tests during tigecycline therapy.[0m
